{'fraction_non_alphanumeric': 0.08712715855572999, 'fraction_numerical': 0.06828885400313972, 'mean_word_length': 4.019685039370079, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Determination of puerarin in biological samples and its application to a pharmacokinetic study by flow-injection chemiluminescence.

A simple and sensitive flow injection-chemiluminescence (FI-CL) method has been developed for the determination of puerarin, based on the fact that puerarin can greatly inhibit CL of the luminol-H₂O₂-haemoglobin system. The inhibition of CL intensity was linear to the logarithm of the concentration of puerarin in the range 0.08-10.0 μg/mL (r²  = 0.9912). The limit of detection was 0.05 μg/mL (3σ) and the relative standard deviation (RSD) for 1.0 μg/mL (n = 11) of puerarin solution was 1.4%. Coupled with solid-phase extraction (SPE) as the sample pretreatment, the determination of puerarin in biological samples and a preliminary pharmocokinetic study of puerarin in rats were performed. The recoveries for plasma and urine at three different concentrations were 89.2-110.0% and 91.4-104.8%, respectively. The pharmacokinetics of puerarin in plasma of rat coincides with the two-compartment open model. The T(½α) , T(½β) , CL/F, V(Z/F), AUC(₀₋t), MRT₀₋∞, T(max) and C(max) were 0.77 ± 0.21 h, 7.55 ± 2.64 h, 2.43 ± 1.02 L/kg/h, 11.40 ± 3.45 L/kg, 56.67 ± 10.65 mg/h/L, 5.04 ± 2.78 h, 1.00 ± 0.35 h and 19.70 ± 4.67 μg/mL, respectively.